Tokai Pharma Reports Updated Phase 2 Data On Galeterone - Quick Facts

(RTTNews) - Tokai Pharmaceuticals, Inc. (TKAI) announced updated interim results from its ongoing Phase 2 clinical trial, ARMOR2, evaluating galeterone as a treatment for patients with castration-resistant prostate cancer, or CRPC. The company reported that the data demonstrated clinically meaningful reductions in prostate-specific androgen levels, a marker of prostate cancer growth. Expanded data in patients with C-terminal loss also provide additional support for galeterone's potential activity in CRPC patients whose tumors express androgen receptor splice variants, which are believed to be associated with resistance to hormonal agents commonly used to treat CRPC.

Galeterone was well tolerated, with approximately 90% of reported adverse events classified as Grade 1 or 2.

"Based on a growing body of evidence, CRPC patients with splice variants resulting in the loss of the C terminal appear to be resistant to hormonal agents commonly used to treat CRPC. We believe that our positive findings in treatment naive patients showing AR C-terminal loss support that galeterone may hold promise as a treatment for these patients. We look forward to initiating our pivotal Phase 3 trial, ARMOR3-SV, in this population in the first half of next year," said Jodie Morrison, president and CEO of Tokai Pharmaceuticals.